Characteristics of Patients
| Characteristics | Control (n = 50) | mHSPC (n = 81) | mCRPC (n = 275) |
|---|---|---|---|
| Age (y) | 71 (69–74) | 69 (63–72) | 72 (66–76) |
| Weight (kg) | 86 (80–99) | 81 (75–92) | 80 (72–92) |
| Injected activity (MBq) | 185 (183–196) | 128 (96–153) | 155 (112–195) |
| Acquisition time (min) | 60 (55–66) | 65 (59–82) | 60 (53–67) |
| PSA (ng/mL)* | 0.4 (0.2–0.8) | 4.0 (1–11) | 130 (37–431) |
| PSMA-VOL (cm3) | 0 | 7 (2–37) | 563 (194–1,358) |
| Site of disease on PSMA-PET | |||
| Bone | 0 | 70 (86%) | 256 (93%) |
| Lymph nodes | 0 | 34 (42%) | 202 (74%) |
| Bone + lymph nodes | 0 | 27 (33%) | 183 (67%) |
| Viscera† | 0 | 10 (12%) | 82 (30%) |
| Bone + lymph nodes + viscera | 0 | 1 (1%) | 59 (22%) |
*Data missing for 10 patients.
↵†Viscera include lung, liver, rectum, pancreas, peritoneal, brain and adrenal.
mHSPC = metastatic hormone-sensitive prostate cancer; mCRPC = metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen.
Qualitative data are number and percentage; continuous data are median and IQR.